Scholarlink

Background <p>ARTO trial was a phase II randomized trial suggesting the benefit of a concomitant treatment strategy including Abiraterone acetate plus predisone (AAP) and stereotactic body radiotherapy (SBRT) in oligometastatic castrate resistant prostate cancer (omCRPC). The object of the current analysis is to explore whether the benefit provided by SBRT to AAP is maintained at later stages of disease after oligoprogression</p> Methods <p>Patients enrolled in ARTO trial in whom a first progression event was reported were divided in two groups according to the treatment approach received, regardless of the initial randomization. After first progression event, Patients in Group A received SBRT on oligoprogressive disease, while patients in group B received second line systemic treatment. Palliative RT was not considered for the purpose of this analysis. Progression-Free survival (PFS) 1 and 2 were defined as time between AAP start and first progression event and time between first and second progression event, death or last follow up, (whichever came first), respectively. Cox regression analysis was performed to compare PFS1 + PFS2 in patients in group A vs Group B. Kaplan–Meier analysis was performed to compare overall survival between the two groups</p> Results <p>Median PFS1 + PFS2 was 45.9 months vs. not reached in group A (<i>n</i> = 43) vs Group B (<i>n</i> = 20), respectively (HR 0.63, 95% CI 0.17–2.33, <i>p</i> value 0.489), no significant difference was detected. Median OS was not reached in neither of the two arms of treatment, with a non-significant trend in favour of the experimental arm (HR 0.50, 95% CI 0.14–1.78, <i>p</i> = 0.284)</p> Conclusions <p>Results from the present analysis show that SBRT after progression may be a viable and feasible option for omCRPC after progression if compared to second line systemic therapy</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)

  • 期刊论文

  • 发表日期：

    2025年2月19日

查看全文
  • Giulio Francolini,
  • Niccolò Bertini,
  • Vanessa Di Cataldo,
  • Pietro Garlatti,
  • Michele Aquilano,
  • Saverio Caini,
  • Alessio Bruni,
  • Gianluca Ingrosso,
  • Rolando Maria D’angelillo,
  • Luca Tagliaferri,
  • Matteo Augugliaro,
  • Luca Triggiani,
  • Silvana Parisi,
  • Giorgia Timon,
  • Fabio Arcidiacono,
  • Giulia Marvaso,
  • Barbara Alicja Jereczek-Fossa,
  • Andrea Lancia,
  • Ciro Franzese,
  • Filippo Alongi,
  • Gabriele Simontacchi,
  • Daniela Greto,
  • Pierluigi Bonomo,
  • Mauro Loi,
  • Giulio Frosini,
  • Luca Burchini,
  • Isacco Desideri,
  • Icro Meattini,
  • Richard K. Valicenti,
  • Lorenzo Livi

摘要

Background

ARTO trial was a phase II randomized trial suggesting the benefit of a concomitant treatment strategy including Abiraterone acetate plus predisone (AAP) and stereotactic body radiotherapy (SBRT) in oligometastatic castrate resistant prostate cancer (omCRPC). The object of the current analysis is to explore whether the benefit provided by SBRT to AAP is maintained at later stages of disease after oligoprogression

Methods

Patients enrolled in ARTO trial in whom a first progression event was reported were divided in two groups according to the treatment approach received, regardless of the initial randomization. After first progression event, Patients in Group A received SBRT on oligoprogressive disease, while patients in group B received second line systemic treatment. Palliative RT was not considered for the purpose of this analysis. Progression-Free survival (PFS) 1 and 2 were defined as time between AAP start and first progression event and time between first and second progression event, death or last follow up, (whichever came first), respectively. Cox regression analysis was performed to compare PFS1 + PFS2 in patients in group A vs Group B. Kaplan–Meier analysis was performed to compare overall survival between the two groups

Results

Median PFS1 + PFS2 was 45.9 months vs. not reached in group A (n = 43) vs Group B (n = 20), respectively (HR 0.63, 95% CI 0.17–2.33, p value 0.489), no significant difference was detected. Median OS was not reached in neither of the two arms of treatment, with a non-significant trend in favour of the experimental arm (HR 0.50, 95% CI 0.14–1.78, p = 0.284)

Conclusions

Results from the present analysis show that SBRT after progression may be a viable and feasible option for omCRPC after progression if compared to second line systemic therapy